Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 12/20 | 0.52 |
| ▸ | CA1 | P00915 | 8/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | CA6 | P23280 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15076431 | 0.85 | CA2 (0.52) | CA2CA1CA9CA12CA14 | |
| SCHEMBL3110388 | 0.85 | CA2 (0.56) | CA2CA1CA9CA12CA14 | |
| SCHEMBL4358922 | 0.85 | CYP3A4 (0.59) | CYP3A4LMNAALDH1A1HSD17B10KDM4E | |
| SCHEMBL7145771 | 0.84 | CA2 (0.55) | CA2CA1CA9CA12CA14 | |
| SCHEMBL29271857 | 0.83 | HSD17B10 (0.62) | CYP3A4LMNAALDH1A1HSD17B10PHLPP2 | |
| SCHEMBL7824801 | 0.82 | CA2 (0.55) | CA2CA1CA9CA12CA14 | |
| SCHEMBL572815 | 0.81 | CYP3A4 (0.56) | CYP3A4LMNAALDH1A1HSD17B10KDM4E | |
| SCHEMBL619999 | 0.81 | LMNA (0.64) | CYP3A4LMNAALDH1A1HSD17B10PTGS2 | |
| SCHEMBL30035568 | 0.81 | CYP3A4 (0.56) | CYP3A4LMNAALDH1A1HSD17B10KDM4E | |
| SCHEMBL30525050 | 0.81 | LMNA (0.64) | CYP3A4LMNAALDH1A1HSD17B10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108963389-A | It is a kind of for lithium-air battery can gelling system and its preparation method and application | 北京师范大学 | 2018-12-07 | — | — | CN | claimed |
| CN-108962627-A | A kind of supercapacitor or capacitor batteries of organic system | 北京师范大学 | 2018-12-07 | — | — | CN | disclosed |
| CN-108963389-A | It is a kind of for lithium-air battery can gelling system and its preparation method and application | 北京师范大学 | 2018-12-07 | — | — | CN | disclosed |
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2334646-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2002018333-A1 | PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
| EP-0556673-B1 | Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as medicaments containing them | HOECHST AG (DE) | 1997-09-17 | — | — | EP | disclosed |
| EP-0556673-A1 | Ortho-substituted benzoylguanidines for the treatment and prophylaxis of heart-rhythm disorders and ischaemically induced damage, as well as inhibition of cell proliferation | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | disclosed |
| EP-0243959-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1992-08-19 | — | — | EP | disclosed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | disclosed |
| US-4377521-A | ANTILIPEMIC | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4138399-A | Sulfamylbenzoic acid | PFIZER INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4124590-A | CARDIOVASCULAR DISORDERS, ANTILIPEMIC AGENTS | PFIZER INC. (US) | 1978-11-07 | — | — | US | disclosed |
| US-3992441-A | ANTILIPEMIC | PFIZER INC. (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | CYP3A4 1447/4885CA2 1/4885CA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.